Does progesterone prophylaxis to prevent preterm labour improve outcome? A randomised double-blind placebo-controlled trial (OPPTIMUM)
Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome. To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes. Double-blind, randomise...
Uloženo v:
| Vydáno v: | Health technology assessment (Winchester, England) Ročník 22; číslo 35; s. 1 - 304 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
NIHR Journals Library
01.06.2018
|
| Témata: | |
| ISSN: | 1366-5278, 2046-4924, 2046-4924 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | Progesterone prophylaxis is widely used to prevent preterm birth but is not licensed and there is little information on long-term outcome.
To determine the effect of progesterone prophylaxis in women at high risk of preterm birth on obstetric, neonatal and childhood outcomes.
Double-blind, randomised placebo-controlled trial.
Obstetric units in the UK and Europe between February 2009 and April 2013.
Women with a singleton pregnancy who are at high risk of preterm birth because of either a positive fibronectin test or a negative fibronectin test, and either previous spontaneous birth at ≤ 34 weeks
of gestation or a cervical length of ≤ 25 mm.
Fibronectin test at 18
to 23
weeks of pregnancy to determine risk of preterm birth. Eligible women were allocated (using a web-based randomisation portal) to 200 mg of progesterone or placebo, taken vaginally daily from 22
to 24
until 34
weeks' gestation. Participants, caregivers and those assessing the outcomes were blinded to group assignment until data collection was complete.
There were three primary outcomes, as follows: (1) obstetric - fetal death or delivery before 34
weeks' gestation; (2) neonatal - a composite of death, brain injury on ultrasound scan (according to specific criteria in the protocol) and bronchopulmonary dysplasia; and (3) childhood - the Bayley-III cognitive composite score at 22-26 months of age.
In total, 96 out of 600 (16%) women in the progesterone group and 108 out of 597 (18%) women in the placebo group had the primary obstetric outcome [odds ratio (OR) 0.86, 95% confidence interval (CI) 0.61 to 1.22]. Forty-six out of 589 (8%) babies of women in the progesterone group and 62 out of 587 (11%) babies of
women in the placebo group experienced the primary neonatal outcome [OR 0.72, 95% CI 0.44 to 1.17]. The mean Bayley-III cognitive composite score of the children at 2 years of age was 97.3 points [standard deviation (SD) 17.9 points;
= 430] in the progesterone group and 97.7 points (SD 17.5 points;
= 439) in the placebo group (difference in means -0.48, 95% CI -2.77 to 1.81).
Overall compliance with the intervention was 69%.
There were no major harms, although there was a trend of more deaths from trial entry to 2 years in the progesterone group (20/600) than in the placebo group (16/598) (OR 1.26, 95% CI 0.65 to 2.42).
In this study, progesterone had no significant beneficial or harmful effects on the primary obstetric, neonatal or childhood outcomes.The OPPTIMUM trial is now complete. We intend to participate in a comprehensive individual patient-level data meta-analysis examining women with a singleton pregnancy with a variety of risk factors for preterm birth.
Current Controlled Trials ISRCTN14568373.
This trial was funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. |
|---|---|
| Bibliografie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ISSN: | 1366-5278 2046-4924 2046-4924 |
| DOI: | 10.3310/hta22350 |